Craig McClain, M.D., contributes to the field of Alcohol Use Disorder research

Dr. Craig McClain has made significant contributions to the field of alcohol use disorder (AUD) research. His pioneering work focuses on using specific bacteria and their metabolites to reduce organ injury caused by alcohol use disorder. Dr. McClain led a groundbreaking multi-center clinical trial that demonstrated the benefits of Lactobacillus rhamnosus GG (LGG), a probiotic bacterium, in treating alcohol-associated liver disease. Additionally, collaborating with Dr. Wenke Feng, they found that LGG-derived substances play a crucial role in promoting gut and liver health in alcohol-treated mice. These findings offer promising prospects for using probiotics as innovative therapies for alcohol-related disorders, addressing a significant public health challenge. Read more about Dr. McClain's accomplishments HERE.